Form 4: Insulet Director Flavia Pease Receives Annual Equity Award of 778 Restricted Stock Units

Insulet Corporation's Director, Flavia Pease, was granted 778 restricted stock units as part of her annual equity award, with vesting scheduled for April 30, 2026.

Summary

• Flavia Pease, a Director of Insulet Corp (PODD), acquired 778 shares of common stock on May 22, 2025.
• This acquisition represents an annual equity award in the form of Restricted Stock Units (RSUs).
• The RSUs were granted at a price of $0, indicating a compensation award rather than a purchase.
• These 778 RSUs are scheduled to vest in full on April 30, 2026.
• Ms. Pease has elected to defer the settlement of these RSUs pursuant to the Insulet Corporation Deferred Compensation Plan for Non-Employee Directors, meaning shares will be issued after her service as a Director terminates.
• Following this transaction, Ms. Pease beneficially owns 3,629 shares of Insulet Corp common stock directly.

Sentiment

Score: 7

Explanation: The document reports a routine annual equity award to a director, which is a positive event for the recipient and generally viewed as a standard practice for aligning director interests with shareholder value. It does not indicate any negative operational or financial news.

Positives

• Director Flavia Pease received an annual equity award of 778 restricted stock units, which aligns her interests with long-term shareholder value.
• The award at a price of $0 indicates a compensation benefit to the director.

Future Outlook

The 778 restricted stock units are scheduled to vest in full on April 30, 2026. Settlement of these RSUs is deferred until the termination of the Director's service, aligning with the Insulet Corporation Deferred Compensation Plan for Non-Employee Directors.

Industry Context

This Form 4 details an insider equity award, a common practice in corporate compensation across various industries, including medical devices, to align management and director interests with shareholder value.

Comparison to Industry Standards

• The granting of restricted stock units (RSUs) as part of director compensation is a common practice across publicly traded companies, including those in the medical device sector like Insulet Corp, serving to align director incentives with long-term shareholder value.

Related Party Transactions

• The acquisition of 778 restricted stock units by Director Flavia Pease is an equity award from Insulet Corporation, representing a transaction with a related party (company director) as part of her compensation.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with long-term shareholder value, potentially encouraging decisions that benefit the company's stock performance.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• The 778 restricted stock units will vest in full on April 30, 2026.
• Shares will be issued following the termination of the Reporting Person's service as a Director, in accordance with her deferral election.

Key Dates

Keywords

Insulet Corp, PODD, Form 4, insider transaction, restricted stock units, RSU, equity award, director compensation, beneficial ownership